New Alzheimer's Prevention Trial Enrolls First Patient
The study tests whether combination drug therapy can prevent Alzheimer's in people with a high-risk gene mutation.
Updated on Oct. 15, 2026 in Alzheimer’s
Live Poll
Should medical research prioritize aggressive prevention trials for populations with a high genetic disease risk?
Researchers have officially enrolled the first participant in a new clinical trial aimed at preventing Alzheimer's disease. The study targets individuals with a specific genetic mutation that leads to early-onset symptoms.
Why it matters
This trial investigates if a combination of medications can delay or prevent Alzheimer's in a population at extremely high genetic risk. It represents a significant effort to shift from treating cognitive decline to preventing the disease before symptoms appear.
This clinical trial is assessing 200 carriers of the PSEN1 gene mutation versus a control group of 40 individuals without the mutation. The study is currently ongoing to determine if combination therapy maintains lower amyloid levels than single-drug treatments.
The players
Banner Alzheimer's Institute
An Arizona-based research organization specializing in the study and prevention of Alzheimer's disease.
University of Antioquia
A Colombian university collaborating on clinical trials for genetic-based Alzheimer's prevention.
National Institute on Aging
A U.S. federal agency providing funding for research on aging and Alzheimer's disease.
The details
The study tests the effectiveness of donanemab, an antibody therapy designed to clear existing amyloid plaques, alongside Roche's nivagacetor, which is intended to limit new amyloid protein production. Participants are randomly assigned to receive one of these medications, a combination of both, or a placebo. Researchers aim to see if clearing brain plaques and then using maintenance therapy can prevent the disease in carriers who typically develop symptoms at age 44.
Timeline
2009: The Alzheimer's Prevention Initiative was formed.
2012: The first API ADAD Colombia trial was announced.
October 15, 2026: The first participant was assigned to the new treatment trial.
Health Landscape
This study builds upon the long-term research framework established by the Alzheimer's Prevention Initiative. It represents a shift in focus toward early, aggressive prevention in populations with defined genetic markers for the disease.
While this study focuses on a specific genetic kindred, its findings may inform future prevention strategies for the broader population. Discuss any concerns about family history or early-onset symptoms with a neurologist or primary care physician.
The takeaway
This trial highlights the promise of combination therapies for Alzheimer's prevention. Keep track of developments in amyloid-clearing research by consulting your physician about new clinical evidence and screening options.
Further reading
Learn more about the latest research in our Alzheimer’s section.
Source note: This article includes information reported by The Manila times.
Live Poll
Should medical research prioritize aggressive prevention trials for populations with a high genetic disease risk?
